Search
Sumario de resultados
TIpos de contenido
Fecha
-
-
New3P Biopharmaceuticals among the 500 fastest growing companies in Spain
This is the first year that the company appears in the ranking established by CEPYME
-
-
NewORYZON awarded EU grant to further explore the role of iadademstat in oncological immunoth...
Project will assess the efficacy of iadademstat in combination with checkpoint inhibitors and/or oncological vaccines
-
NewGENESIS Biomed continues growing and adding value in biomedical sector
Since it was established in May 2017, the company has worked on more than 253 consultancy projects, mobilised over €67.5 million, and managed 19 rounds of funding for clients, including two in 2022
-
NewBarcelona Science Park, a strategic hub for public R&D&i of excellence
2021 was a year full of challenges and milestones achieved for public research groups and institutes working at the Barcelona Science Park
-
Press releaseGroup of experts proposes actions to boost use of new technologies in biotechnology sector
AseBio and ASD present in Madrid the document with the main conclusions on the state of new technologies in the industry. One of the proposals for action is to train professionals and develop a
-
Press release
Las soluciones biotecnológicas se abren paso ante el desafío climático y energético
AseBio and FUNDECYT-PCTEx are holding the fifth edition of the Green Innovation Forum in Mérida, Extremadura. More than 300 experts from the Spanish biotechnology sector have gathered to promote a new
-
Press release
AseBio closes out year with 1,000 lines of research registered
86.6% of studies under way focus on improving people’s health and nearly 14% on protecting the planet. Of all these innovations, 203 are already available on the market or ready for exploitation Of
-
NewAseBio closes out year with 1,000 lines of research registered
86.6% of studies under way focus on improving people’s health and nearly 14% on protecting the planet. Of all these innovations, 203 are already available on the market or ready for exploitation
-
NewOxolife receives a 2.4M€ grant to develop a new treatment for infertility related to polyc...
Oxolife, in collaboration with Cordoba’s University, will advance from preclinical to phase II clinical trials in the next 2 years
-
NewORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-lin...
Clinical efficacy signals were robust, with an objective response rate (ORR) of 81%; of these, 64% were complete remissions (14 CR/CRi) and 36% partial remissions (8 PR)
-
-
Offer
Investigador/a
-
-
-
Offer
Técnico Proyecto PADIGA
-
EventWe present BIOSPAIN 2023
With this event, we intend to announce the most important and influential edition of all as it will be held for the first time in 20 years in Barcelona, the epicentre of biotechnology in Europe
-
NewHow a biotech firm from Granada found its place in the competitive international market
LentiStem Biotech, a spin-off that has just celebrated its sixth anniversary, decided to focus on CAR-T therapies, developing technology that instead of competing builds synergies
-
Offer
Coordinador/a clínico
-
